Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Thumbnail
View
Author
Burchert, Andreas
SESQUES, Pierre ORCID
Fransecky, Lars ORCID
Rejeski, Kai ORCID
Barba, Pere ORCID
Bücklein, Veit ORCID
IACOBONI, GLORIA ORCID
Date
2022-08-23
Permanent link
https://hdl.handle.net/11351/9612
DOI
10.1182/bloodadvances.2022007776
ISSN
2473-9529
WOS
000863968700001
PMID
35793454
Share on TwitterShare on FacebookShare on TelegramShare on WhatsappShare on Linkedin

Show full item record
Keywords
Stem cell; Hematotoxicity; T-cell
Bibliographic citation
Rejeski K, Burchert A, Iacoboni G, Sesques P, Fransecky L, Bücklein V, et al. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv. 2022 Aug 23;6(16):4719-25.
Audience
Professionals
This item appears in following collections

The following license files are associated with this item: